جستجوی استاد راهنمای دانشگاهی

Philipp Neumann is a Professor and Chair of High-Performance Computing at Helmut Schmidt University since 2019. Previously, he held roles including Senior Researcher at the German Climate Computing Center (2016–2019), Postdoc at the University of Hamburg (2017–2019), and completed his Habilitation in Scientific Computing at TU Munich (2019). He transitioned to DESY/Universität Hamburg in May 2024. Education : PhD (Dr. rer. nat.) in Scientific Computing at TU Munich (2008–2013) Habilitation in Scientific Computing at TU Munich (2019) Studies in Technomathematics at Friedrich-Alexander University Erlangen-Nuremberg (2003–2008) Research Interests focus on high-performance computing, parallel and distributed systems, computational science, and applications in climate modeling. His work bridges computational methods with medical challenges, including surgical simulation training, wound healing mechanisms, and gastrointestinal pathology. Professional Activities include leadership roles in major conferences such as steering committee member for ISPDC (since 2021) and program committee roles in IPDPS, ICCS, and IEEE Cluster. He also managed the DFG priority program SPPEXA (2013–2016). Labs/Teams include the Chair for High-Performance Computing at Helmut Schmidt University and collaborations with the German Climate Computing Center. His current work at DESY/Universität Hamburg likely expands these computational efforts into interdisciplinary research.

• High-Performance Computing
• Scientific Computing
• Parallel and Distributed Systems
• +۴ مورد دیگر

Prof. Dr. med. Franz Lennard Ricklefs is a Senior Physician and Head of the Working Group at the Department of Neurosurgery, University of Hamburg Faculty of Medicine. He is a Medical Specialist in Neurosurgery with cross-disciplinary expertise in neuro-oncology, molecular pathology, and extracellular vesicle research. Affiliations: University Medical Center Hamburg-Eppendorf (UKE), European Liquid Biopsy Society (ELBS), International Consortium on Meningiomas (ICOM) Research Interests: His work focuses on neurosurgical oncology, particularly glioblastoma and meningioma pathobiology. He investigates DNA methylation patterns, extracellular vesicle biomarkers, and liquid biopsy implementation in clinical neuro-oncology. Additional interests include surgical outcomes for epilepsy and aneurysm management. Article Trends: Over the last decade, Dr. Ricklefs has published extensively on: Extracellular vesicle applications as liquid biopsy markers DNA methylation subclasses for glioblastoma and meningioma Multicenter surgical outcome benchmarking Immune evasion mechanisms in neuro-oncology Technological innovations in neurosurgical visualization Molecular characterization of rare CNS tumors Professional Contributions: He co-authored the MISEV2023 guidelines for extracellular vesicle studies and participates in international consensus reviews for meningioma classification. His collaborations span institutions across Europe and North America.

• Neurosurgery
• Neuro-oncology
• Molecular Neurobiology
• +۵ مورد دیگر

Dr. Andrew Bassett serves as Head of the Cellular and Gene Editing Research group at the Wellcome Sanger Institute, where he develops cutting-edge genome engineering techniques using human pluripotent stem cells to investigate neurodegenerative diseases including Alzheimer's and Parkinson's. His work focuses on scaling genetic screening approaches and improving CRISPR specificity for modeling complex disease mechanisms. His academic training includes: PhD at the MRC Laboratory of Molecular Biology (MRC-LMB) with Andrew Travers on chromatin remodelling in heterochromatin formation Postdoctoral research with David Baulcombe at the University of Cambridge studying small RNA roles in chromatin modification Additional postdoctoral work with Chris Ponting at the MRC Functional Genomics Unit (MRC-FGU) in Oxford, where he pioneered CRISPR applications in Drosophila Bassett's research program centers on developing advanced genome engineering methodologies for precise modulation of gene expression networks during development and neurodegeneration. His group specializes in creating complex editing events (SNPs, paired knockouts, enhancer perturbations) within iPSC-derived models, with particular emphasis on epigenetic regulation and transcriptional control. Current projects integrate single-cell 'omics and phenotypic assays to decode genetic causes of neurodegenerative disorders through the OpenTargets consortium. Analysis of his 15 most recent publications reveals dominant trends in CRISPR technology development (35%), neurodegenerative disease modeling (30%), and single-cell functional genomics (25%). His work consistently bridges methodological innovation with disease mechanism studies, increasingly incorporating multi-omics approaches and expanding into cancer immunology and infectious disease applications since 2022. As group leader, Bassett mentors postdoctoral researchers and PhD students while securing major funding for genome engineering initiatives. His team operates within the Sanger Institute's Cellular Operations division and maintains critical partnerships with the OpenTargets consortium for therapeutic target validation. The laboratory specializes in high-throughput screening platforms using iPSC-derived neural and microglial models, with recent methodological advances including scSNV-seq and ONE-STEP tagging systems that significantly enhance precision genome editing capabilities.

• Genome Engineering
• Neurodegenerative Diseases
• Stem Cell Research
• +۵ مورد دیگر

Michael Boutros is a Full Professor at Heidelberg University and Head of Division at the German Cancer Research Center (DKFZ). He currently serves as Dean of the Medical Faculty at Heidelberg University (since 2023) and Director of the Marsilius Kolleg (since 2020). He has held leadership roles including Coordinator of the Functional and Structural Genomics Program at DKFZ (2014–2023) and Acting Scientific Director (2015–2016). His academic base is within the Medical Faculty, focusing on molecular oncology and functional genomics. PhD, Witten/Herdecke University (1993–1996) Postdoctoral Research, Harvard Medical School (1999–2003) MPA, John F. Kennedy School of Government, Harvard University (1999–2001) Additional training: Cold Spring Harbor Laboratory, SUNY Stony Brook His research centers on Wnt signaling, functional genomics, and cancer pathways. He leads major research initiatives such as CRC 1324 on Wnt signaling and the ERC Synergy Grant DECODE. His work integrates high-throughput screening, CRISPR, and systems biology to dissect signaling networks in cancer and development. He has pioneered genome-wide RNAi and CRISPR screens to identify novel regulators of Wnt signaling across models. The 15 most recent articles reflect a strong focus on Wnt pathway regulation using functional genomics in both Drosophila and mammalian systems. Themes include high-throughput screening, CRISPR-based validation, cross-species conservation, and therapeutic targeting. Keywords span Cancer Biology, Systems Biology, and Signal Transduction, with subfields like RNAi, ubiquitination, stem cell regulation, and machine learning in image analysis. Michael Boutros has received numerous scientific honors: Elected member, Leopoldina National Academy of Sciences (2022) Elected member, Heidelberg Academy of Sciences (2022) EMBO Member (2013) ERC Advanced Grant (2012) Johann-Georg Zimmermann Research Award (2007) EMBO Young Investigator (2005) Member, 'Die Junge Akademie' (2003) He has been a recipient of the Emmy-Noether Program, McCloy Fellowship, Boehringer Ingelheim PhD Fellowship, Studienstiftung Fellowship, and Fulbright Fellowship. As a mentor and research leader, he has supervised numerous early-career scientists and coordinated large collaborative grants including the FP7 'CancerPathways' project. He currently serves as Speaker of the Research and Strategy Commission at Heidelberg University and Managing Director of the Health and Life Science Alliance Heidelberg Mannheim. He leads the CRC 1324 on Wnt signaling and is Coordinating PI of the ERC Synergy Grant DECODE. He is also Spokesperson of DFG Research Group 1036 and Coordinator of the former FP7 Coordinated Project 'CancerPathways'. His lab employs cutting-edge functional genomics tools to decode signaling networks in cancer and development.

• Functional Genomics
• Structural Genomics
• Wnt Signaling
• +۷ مورد دیگر

Nikolaus Rajewsky is a leading Professor at the Max Delbrück Center for Molecular Medicine (MDC) and Charité – Universitätsmedizin Berlin , where he founded and directs the Berlin Institute for Medical Systems Biology (BIMSB) . His lab integrates experimental (biochemistry, molecular biology) and computational (bioinformatics, physics) approaches to study RNA regulation in gene expression , with applications to developmental biology, regeneration, neurodegenerative diseases, and cancer . Using model systems like C. elegans , planaria, and human brain organoids, his team pioneers cutting-edge methods such as MirDeep , DistMap , and FLAM-seq for RNA analysis. His research focuses on single-cell transcriptomics , spatial RNA sequencing , and circular RNA (circRNA) regulation , revealing novel roles for circRNAs like CDR1as in neuropsychiatric disorders. Recent work includes 3D tumor microenvironment mapping and computational modeling of RNA metabolism in diseases. Scientific Awards : Gottfried Wilhelm Leibniz Prize (2012) EMBO Membership (2010) Honorary PhD, Sapienza University of Rome (2014) Berlin Science Award (2009) His team's recent articles highlight breakthroughs in 3D spatial transcriptomics , circRNA degradation mechanisms , and mitochondrial disease modeling using human brain organoids. The lab actively collaborates with clinical partners across Charité and European institutions, driving the LifeTime initiative for cell-based interceptive medicine.

• RNA Biology
• Gene Regulation
• Single-Cell Transcriptomics
• +۶ مورد دیگر

G. Petur Nielsen, MD is a Professor of Pathology at Harvard Medical School and serves as Subspecialty Head, Bone and Soft Tissue Pathology at Massachusetts General Hospital . With a clinical focus on bone and soft tissue tumors, his expertise spans diagnostic pathology, molecular genetics of neoplasms, and ancillary testing applications. Research interests center on Pathology and biology of bone/soft tissue tumors Molecular genetics of bone and soft tissue neoplasms Chordoma and sarcoma research Epithelioid vascular tumor differentiation Mesenchymal tumors of the female genital tract His work includes landmark studies on tumor misdiagnosis rates, immunohistochemical profiling, and genomic analysis of chordomas. Scientific contributions appear in leading journals like Nature and American Journal of Surgical Pathology , with major emphasis on Molecular tumor classification Mutational signature analysis Translational oncology Diagnostic accuracy improvement Genomic instability mechanisms

• Bone and Soft Tissue Pathology
• Molecular Genetics of Bone Tumors
• Chordoma Research
• +۵ مورد دیگر

Professor Ghazaleh Tabatabai serves as Head of Department for Clinical and Experimental Neuro-Oncology at the Hertie Institute for Clinical Brain Research, University of Tübingen. She leads a multidisciplinary research group focused on translational neuro-oncology with active collaborations through the German Glioma Network, German Cancer Consortium (DKTK), European Organisation for Research and Treatment of Cancer (EORTC), European Association of Neuro-Oncology (EANO), and International Consortium on Meningioma (ICOM). Her research program centers on molecular mechanisms of tumorigenesis, therapy resistance, and treatment-induced vulnerabilities in nervous system tumors. The laboratory employs CRISPR screening technologies, molecular profiling, and preclinical models to identify therapeutic targets, with particular expertise in glioma and meningioma biology. Current projects span from discovery through validation to clinical application, including phase I/II trials of novel therapies such as CureVac's mRNA vaccine candidate CVGBM. Recent publications demonstrate leadership in molecular classification of meningiomas, CRISPR-based target discovery, immunotherapy development, and clinical trial design. Her work on the TRACE app for patient-reported outcomes and the PRIDE trial for dose-escalated radiation therapy represents significant clinical translation efforts. The 2024-2025 publication record shows strong productivity with high-impact papers in Neuro-Oncology, Nature Medicine, and Genome Biology. Elected spokesperson of the DFG Board for Neuroscience (2024) Active participation in EANO guideline development Leadership in multiple international consortia including ICOM Principal investigator for clinical trials including N2M2/NOA-20 umbrella trial Professor Tabatabai mentors a large research team including PhD students, medical doctoral candidates, and postdoctoral researchers. Her laboratory maintains active clinical collaborations across neurosurgery, radiation oncology, and medical oncology departments. She is featured in the 'Key To My Research' podcast discussing tumor intelligence and regularly presents at major neuro-oncology conferences including ASCO, EANO, and SNO.

• Neuro-Oncology
• Glioma Biology
• Meningioma Research
• +۵ مورد دیگر

Prof. Heike Krebber is a Professor for Molecular Genetics at Georg-August University Göttingen, Germany. Her research focuses on mRNA quality control and non-coding RNA functions, using the model organism Saccharomyces cerevisiae. She has held positions at the DKFZ (Heidelberg), Harvard Medical School, and Philipps-Universität Marburg. Her work addresses how mRNA processing defects contribute to diseases like cancer and neurodegeneration. Education & Positions: PhD (1996), Deutsches Krebsforschungszentrum Heisenberg Fellow (2006) Habilitation in Molecular Biology (2005) Professor since 2010 at Georg-August University Research Interests: Her lab investigates: RNA quality control mechanisms ensuring proper mRNA maturation and export Functions of non-coding RNAs (e.g., lncRNAs in iron metabolism and telomerase) Ribosome assembly and translation termination pathways Stress-induced bypass of mRNA quality control Awards: Heisenberg Fellowship (2006) Grants & Teams: Leads the Molecular Genetics group at the Institute for Microbiology and Genetics. Collaborates with the IMPRS Molecular Biology and GZMB (Molecular Biology of Cells) programs. Labs & Affiliations: Her group is part of the GGNB network, focusing on Microbiology and Biochemistry. The lab’s work spans fundamental molecular mechanisms with translational disease relevance.

• mRNA Quality Control
• ncRNA Functions
• Molecular Biology
• +۳ مورد دیگر

Prof. Dr. Michael Sattler is a Full Professor of Biomolecular NMR at the Technical University of Munich (TUM) and Director of the Institute of Structural Biology at Helmholtz Zentrum München. He leads the Molecular Targets & Therapeutics Center and directs the Bavarian NMR Center. His research focuses on integrative structural biology, elucidating molecular mechanisms of biological pathways through advanced NMR techniques combined with cryo-EM, SAXS, and crystallography. Key areas include RNA regulation (alternative splicing, non-coding RNAs), disease mechanisms (e.g., spinal muscular atrophy), and structure-based drug discovery for cancer and infectious diseases. Education & Career PhD in Chemistry (1995) from Goethe University Frankfurt Postdoc at Abbott Laboratories (Chicago) and EMBL Heidelberg (Group Leader, 1997–2007) Full Professor at TUM since 2007 Director roles at Helmholtz Munich and Bavarian NMR Center since 2007 Research Highlights Prof. Sattler's work has revealed structural insights into RNA:protein interactions (e.g., SF1-RNA, U2AF), SMN Tudor domain recognition, and drug discovery strategies targeting Hsp90 and viral proteases. His lab pioneered integrative structural biology approaches and established high-end NMR facilities like the 1.2 GHz spectrometer. Awards & Recognition ERC Synergy Grant (2023) Leopoldina Membership (2017) EMBO Membership (2012) Erwin Schrödinger Prize (2020) Teaching & Leadership He teaches advanced courses in NMR spectroscopy, biochemistry, and structural biology at TUM. Leads EU Horizon-funded training networks (AEGIS, RNAct) and organizes international conferences on NMR and drug discovery.

• Biomolecular NMR Spectroscopy
• Structural Biology
• RNA Regulation
• +۷ مورد دیگر

Prof. Dagmar Wirth is a Research Professor and Head of the 'Model Systems for Infection and Immunity' research group at the Helmholtz Centre for Infection Research (HZI). Her work focuses on gene regulation, viral infections, and immune evasion mechanisms, with a particular emphasis on developing genetically modified mouse models for studying infectious diseases and immune responses. She leads the Service Unit 'Transgenic Mice' (TGSM), providing expertise in transgenic model systems to the HZI community. Affiliations: HZI (since 2004), previously at the Medical University of Hannover. Education: Chemistry studies in Braunschweig, PhD at GBF (now HZI), postdoctoral research on viral recombination and gene therapy. Her research interests include viral pathogenesis (e.g., Kaposi's sarcoma-associated herpesvirus), engineered cell-based therapies, and controlled drug delivery systems using macrophages and nanoparticles. She has pioneered models for hepatitis C virus infection in mice and developed biosensors to detect bacterial infections. Publications: Over 150 peer-reviewed articles, focusing on virology, immunology, and genetic engineering. Recent work includes studies on antibacterial coatings for implants, ultrasound-activated drug release, and the role of senescence in herpesvirus infection. Labs/Teams: Leads the MSYS group and collaborates with teams in virology, immunology, and biomedical engineering. Active in developing 3D in vitro models for studying infection and immune responses.

• Virology
• Immunology
• Gene Regulation
• +۴ مورد دیگر

Stefan Hüttelmaier is a Full Professor of Molecular Cell Biology at Martin-Luther University Halle-Wittenberg, Germany. He leads the Core Facility Imaging at the Charles Tanford Protein Center and directs research into RNA-binding proteins' roles in cancer. His career includes postdoctoral work at Albert Einstein College of Medicine and leadership roles in the RTG 1591 research group. His work focuses on RAVER1 protein dynamics, perinucleolar compartments, and RNA metabolism in cancer progression. Education: PhD in Biotechnology (2000, University of Braunschweig), postdoctoral training at Albert Einstein College of Medicine (2001–2004). Academic milestones include Associate Professor (2009) and Full Professor (2014) positions. Research spans RNA-protein interactions, cancer biology, and translational mechanisms in tumors. Key research interests include RNA-binding proteins' roles in cancer (RAVER1, IGF2BP1), alternative splicing, and miRNA regulation. His lab investigates how these molecules influence cancer cell behavior, metastasis, and therapeutic resistance. Recent work highlights druggable targets like IGF2BP1 and mechanisms linking RNA modifications to oncogenesis. Leadership roles include RTG 1591 speaker and Core Facility director. Publications emphasize RNA biology in cancer, with contributions to understanding post-transcriptional control and therapeutic strategies targeting RNA pathways. His interdisciplinary approach combines molecular biology, biochemistry, and computational modeling to address clinical challenges in oncology.

• Molecular Biology
• Cancer Biology
• RNA Biology
• +۳ مورد دیگر

Prof. Dieter Saur is a Professor of Translational Tumor Research at the Technical University of Munich (TUM) and Head of the Department at the German Cancer Research Center (DKFZ). His research focuses on developing personalized cancer therapies through mechanistic studies of tumor-relevant genetic alterations, with a particular emphasis on pancreatic and gastrointestinal cancers. Education: Studied medicine at Ludwig Maximilian University of Munich, earned a doctorate in neurogastroenterology, completed specialist training in gastroenterology and gastrointestinal oncology, and habilitation in internal medicine. He became a senior physician at University Hospital rechts der Isar before his current roles at TUM and DKFZ. Research Interests: Translational cancer research, genetic drivers of tumor progression, early detection methods, and targeted therapies for pancreatic and gastrointestinal cancers. He uses genetically engineered mouse models and organoid systems to study tumor heterogeneity and therapeutic resistance. Awards: Recipient of prestigious grants like the ERC Consolidator Grant (2015) and awards such as the Martin Wienbeck Award (2014) and Rising Star Award (2006). His work bridges basic science and clinical translation, emphasizing interdisciplinary approaches. Labs/Teams: Leads the Translational Tumor Research group at TUM and collaborates with the DKFZ to advance preclinical and clinical cancer research. Key projects include exploring KRAS signaling pathways, tumor microenvironment dynamics, and immune checkpoint therapies.

• Translational Cancer Research
• Genetic Alterations in Cancer
• Personalized Medicine
• +۳ مورد دیگر

Dr. Johannes C. Hellmuth leads the DKTK Junior Clinical Cooperation Unit for Non-Coding Cancer Biology at the Ludwig Maximilian University of Munich (LMU Klinikum), affiliated with the Department of Pathology under the School of Medicine. His research focuses on exploiting vulnerabilities in the non-coding genome of cancer cells, particularly through super-enhancer analysis and CRISPRi screening. Research Interests: Functional interrogation of the non-coding genome Super-enhancer proteomes in oncogenesis Transcriptional condensates as therapeutic targets Non-invasive super-enhancer diagnostics Publication Trends: Recent work spans epigenetic regulation in lymphomas, super-enhancer dependencies in cancer, and chromatin dynamics during immune cell differentiation, with a focus on integrating omics data for personalized therapies.

• Non-Coding Cancer Biology
• Super-Enhancer Regulation
• CRISPRi Screening
• +۳ مورد دیگر

Dr. Emiel van der Vorst is a cardiovascular researcher focusing on atherosclerosis, immunometabolism, and translational medicine . His work spans molecular mechanisms, therapeutic targeting, and omics-based approaches. Affiliation: Institute for Molecular Cardiovascular Research (IMCAR) Research Focus: Chemokine signaling, microRNA therapeutics, immune-metabolic interactions Research Trends: Recent publications highlight his exploration of microRNA-26b in metabolic liver disease GPR55 receptor in cardiomyocyte adaptation calcium-sensing receptor in sex-specific atherosclerosis aryl hydrocarbon receptor in gut-liver-cardiovascular axis His work integrates nanomedicine, genetic models, and clinical biomarker development .

• Cardiovascular Research
• Atherosclerosis
• Immunology
• +۶ مورد دیگر

Dr. Johannes Greiner is a researcher at the Faculty of Biology at University of Bielefeld, Germany, with a strong research focus on stem cell biology, particularly neural crest-derived stem cells and their molecular regulation. His work bridges fundamental cellular mechanisms with potential clinical applications in regenerative medicine and cancer therapy. Dr. Greiner's primary research interests include: Neural crest-derived stem cell characterization and differentiation pathways NF-κB signaling mechanisms in stem cells and disease contexts Sex-specific differences in stem cell behavior and differentiation potential Osteogenic and neuronal differentiation processes Cancer stem cell biology and therapeutic targeting strategies Analysis of Dr. Greiner's publication record from 2011-2024 reveals a consistent research trajectory focused on molecular mechanisms governing stem cell behavior, with particular emphasis on NF-κB pathway regulation and sex-based differences in cellular responses. His work demonstrates methodological diversity, employing techniques ranging from single-cell analysis to molecular pathway interrogation, reflecting a comprehensive approach to understanding stem cell function in both health and disease contexts. Dr. Greiner has contributed to numerous publications in specialized journals focusing on molecular biology, regenerative medicine, and cancer research, with collaborative work spanning multiple research groups. His research output demonstrates sustained productivity and evolving focus toward understanding the fundamental mechanisms that govern stem cell behavior and their implications for human health.

• Stem Cell Research
• Neural Crest-Derived Stem Cells
• NF-κB Signaling
• +۳ مورد دیگر